Dacarbazine clinical trials
Also written DTIC and DTIC-Dome.
Its developmentBy Bayer, step by step1 company-led study, furthest phase 4: when each phase was reached, its deals, target and what is ahead.How each study uses Dacarbazine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Dacarbazine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 27 May 1975 · DTIC-DOME · NDA 017575 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
74 studies that test it; most in 2007 (6); 1 more planned to start later
| Year | Studies |
|---|---|
| 1996 | 1 |
| 1997 | 1 |
| 1998 | 3 |
| 1999 | 2 |
| 2000 | 1 |
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 2 |
| 2005 | 3 |
| 2006 | 2 |
| 2007 | 6 |
| 2008 | 3 |
| 2009 | 4 |
| 2010 | 5 |
| 2011 | 4 |
| 2012 | 5 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 5 |
| 2018 | 3 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 62
University of Cologne (4) · M.D. Anderson Cancer Center (3) · Bristol-Myers Squibb (3) · Takeda (2) · City of Hope Medical Center (2) · Fondazione Italiana Linfomi - ETS (2) · University of Washington (2) · Eastern Cooperative Oncology Group (2)
Often tested with
Tested in the same studies.
Vinblastine (27) · Doxorubicin (25) · Brentuximab Vedotin (16) · Bleomycin (12) · Cisplatin (8) · Cyclophosphamide (7) · Etoposide (6) · Vincristine (6)
Related medicines
As reviewed, each with the page that says it.
- One of Alkylating agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 3 phase 3 studies under way
Dacarbazine is the comparator. A study of two new drugs counts under both.
- 1Naporafenib · Erasca, Inc. · next primary completion Apr 2028
- 1Darovasertib · IDEAYA Biosciences · next primary completion Jan 2027
- 1Anzutresgene autoleucel · Immatics US, Inc. · next primary completion Jan 2028
Reaching primary completion within a year · 6, 1 in phase 3
Studies that test Dacarbazine, phase 3 first.
- Nov 2026High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)Phase 3 · Gustave Roussy, Cancer Campus, Grand Paris
- Jan 2027Doxorubicin Plus Dacarbazine Versus Doxorubicin Alone as First-Line Therapy for Metastatic or Recurrent Uterine LeiomyosarcomaPhase 2 · Blokhin's Russian Cancer Research Center
- Jan 2027Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17Phase 2 · St. Jude Children's Research Hospital
- Apr 2027A Study of BV-AVD in People With Bulky Hodgkin LymphomaPhase 2 · Memorial Sloan Kettering Cancer Center
- Oct 2027Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and AbovePhase 2 · University of Virginia
- Oct 2027PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin LymphomaPhase 2 · M.D. Anderson Cancer Center
Studies
Open first, then newest update. How each study uses Dacarbazine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 76
- BrECADD Therapy in Stage 2 B-IV Hodgkin LymphomaRecruitingPhase 2University of MiamiNCT07002216Written as DacarbazineHow we know
- Doxorubicin Plus Dacarbazine Versus Doxorubicin Alone as First-Line Therapy for Metastatic or Recurrent Uterine LeiomyosarcomaRecruitingPhase 2Blokhin's Russian Cancer Research CenterNCT07942168Written as dacarbazineHow we know
- Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard TreatmentRecruitingPhase 2City of Hope Medical CenterNCT07275216Written as DacarbazineHow we know
- Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin LymphomaRecruitingPhase 2University of WashingtonNCT06745076Written as DacarbazineHow we know
- A Study of BV-AVD in People With Bulky Hodgkin LymphomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06377566Written as DacarbazineHow we know
- Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)RecruitingPhase 3Advenchen Laboratories, LLCNCT03016819Written as DacarbazineHow we know
- A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in IndiaRecruitingPhase 4TakedaNCT06831370Written as DacarbazineHow we know
- Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE)RecruitingPhase 2Swiss Cancer InstituteNCT06835049Written as DacarbazineHow we know
- Nivo40-AVD for Advanced Classic Hodgkin LymphomaRecruitingPhase 2National Medical Research Radiological Centre of the Ministry of Health of RussiaNCT06984146Written as DacarbazineHow we know
- High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)RecruitingPhase 3Gustave Roussy, Cancer Campus, Grand ParisNCT04221035Written as DacarbazineHow we know
- BV-AVD-R Treatment Children Hodgkin's LymphomaEnrolling by invitationPhase 2Beijing Children's HospitalNCT06201507Written as DacarbazineHow we know
- A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin LymphomaActive, not recruitingPhase 1/2TakedaNCT02979522Written as DacarbazineHow we know
- Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin LymphomaActive, not recruitingPhase 2City of Hope Medical CenterNCT03712202Written as DacarbazineHow we know
- PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin LymphomaActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT05922904Written as DacarbazineHow we know
- Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin LymphomaActive, not recruitingPhase 2Academic and Community Cancer Research UnitedNCT03233347Written as DacarbazineHow we know
- Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II StudyActive, not recruitingPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT03517137Written as DacarbazineHow we know
- Adjuvant Therapy of Skin Melanoma With Alpha Interferon and NaderinCompletedPhase 2MIPO ClinicNCT07671495Written as Dacarbazine (DTIC)How we know
- CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine LeiomyosarcomaCompletedPhase 2Stanford UniversityNCT04727242Written as DacarbazineHow we know
- Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17Active, not recruitingPhase 2St. Jude Children's Research HospitalNCT03755804Written as DTICHow we know
- Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin LymphomaCompletedPhase 2Northwestern UniversityNCT01476410Written as dacarbazineHow we know
See all 76 studies that test Dacarbazine →
Given beside what is tested · 60 — Dacarbazine is usual care or a partner of the new treatment
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabRecruitingPhase 3National Cancer Institute (NCI)NCT05675410Written as DacarbazineHow we know
- Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective TrialRecruitingPhase 2Sun Yat-sen UniversityNCT07847359Written as DacarbazineHow we know
- Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHLRecruitingPhase 2M.D. Anderson Cancer CenterNCT07551583Written as DacarbazineHow we know
- Brentuximab Vedotin in Early Stage Hodgkin LymphomaRecruitingPhase 3University College, LondonNCT04685616Written as DacarbazineHow we know
- Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT AssessmentRecruitingPhase 2/3Children's Cancer Group, ChinaNCT06563245Written as DacarbazineHow we know
- First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)RecruitingPhase 3State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of RussiaNCT04638790Written as DacarbazineHow we know
- Treatment for Classical Hodgkin Lymphoma in Children and AdolescentsRecruitingNot applicableGALIA AVRAHAMINCT02797717Written as DacarbazineHow we know
- Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin LymphomaActive, not recruitingPhase 2St. Jude Children's Research HospitalNCT01920932Written as Dacarbazine(R)How we know
- Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin LymphomaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT03907488Written as DacarbazineHow we know
- Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT03407144Written as dacarbazineHow we know
- Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin LymphomaCompletedPhase 2Massachusetts General HospitalNCT02505269Written as DacarbazineHow we know
- Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin LymphomaActive, not recruitingPhase 2Northwestern UniversityNCT06164275Written as DacarbazineHow we know
- Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin LymphomaCompletedNot applicableMemorial Sloan Kettering Cancer CenterNCT01868451Written as DacarbazineHow we know
- A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)CompletedPhase 1AstraZenecaNCT00600496Written as DacarbazineHow we know
- A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin LymphomaCompletedPhase 3TakedaNCT01712490Written as dacarbazineHow we know
- A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)Active, not recruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT03033914Written as dacarbazineHow we know
- Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's LymphomaActive, not recruitingPhase 2Henan Cancer HospitalNCT04067037Written as DacarbazineHow we know
- Clinical Trial of Brentuximab Vedotin in Classical Hodgkin LymphomaTerminatedPhase 2Seagen Inc.NCT03646123Written as dacarbazineHow we know
- Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin LymphomaCompletedPhase 1/2National Cancer Institute (NCI)NCT01771107Written as DacarbazineHow we know
- A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)TerminatedPhase 2/3PTC TherapeuticsNCT05269355Written as DacarbazineHow we know
Showing 20 of 60.
As the comparator · 34 — what is tested is compared with Dacarbazine
- SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaRecruitingPhase 3Immatics US, Inc.NCT06743126Written as DacarbazineHow we know
- A Phase II Trial of LM103 in Advanced MelanomaRecruitingPhase 2Suzhou BlueHorse Therapeutics Co., Ltd.NCT07310784Written as Dacarbazine, temozolomide, paclitaxel, carboplatin/cisplatinHow we know
- Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal MelanomaCompletedPhase 2Immunocore LtdNCT03070392Written as DacarbazineHow we know
- Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and AdolescentsCompletedPhase 3University of GiessenNCT02684708Written as cyclophosphamide, vincristine, prednisone, dacarbazineHow we know
- A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)Active, not recruitingPhase 3Erasca, Inc.NCT06346067Written as DacarbazineHow we know
- IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaActive, not recruitingPhase 2/3IDEAYA BiosciencesNCT05987332Written as DacarbazineHow we know
- Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's LymphomaCompletedPhase 3European Organisation for Research and Treatment of Cancer - EORTCNCT00049595Written as dacarbazineHow we know
- Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant MelanomaTerminatedPhase 3American Regent, Inc.NCT00087776Written as DacarbazineHow we know
- A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic MelanomaCompletedPhase 3Shanghai Junshi Bioscience Co., Ltd.NCT03430297Written as Dacarbazine 1000mg/m2 Q3WHow we know
- Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin LymphomaCompletedPhase 3University College, LondonNCT00678327Written as dacarbazineHow we know
- S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin LymphomaCompletedPhase 2SWOG Cancer Research NetworkNCT00822120Written as dacarbazineHow we know
- Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic MelanomaCompletedPhase 3Bristol-Myers SquibbNCT01721772Written as DacarbazineHow we know
- A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)CompletedPhase 3Bristol-Myers SquibbNCT01721746Written as DacarbazineHow we know
- Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive MelanomaCompletedPhase 3PfizerNCT01763164Written as DacarbazineHow we know
- Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-KitTerminatedPhase 3AB ScienceNCT01280565Written as DacarbazineHow we know
- Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)CompletedPhase 2Merck Sharp & Dohme LLCNCT01704287Written as DacarbazineHow we know
- A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma PatientsStatus unknownPhase 2OrienGene Biotechnology Ltd.NCT04200040Written as Dacarbazine (DTIC)How we know
- A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant MelanomaCompletedPhase 3CelgeneNCT00864253Written as DacarbazineHow we know
- A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal MelanomaCompletedPhase 2The Clatterbridge Cancer Centre NHS Foundation TrustNCT01551459Written as DacarbazineHow we know
- Procarbazine Hydrochloride Capsule (Natulan®) Clinical Trial ProtocolStatus unknownNot applicableLee's Pharmaceutical LimitedNCT02800447Written as ABVDHow we know
Showing 20 of 34.
What changed recently
From the registry's own updates since Oct 20, 2026.
Results posted1
Newly registered1
Codes
What other systems call Dacarbazine · ClinicalTrials.gg INT007295
- MeSH (NLM) D003606DacarbazineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 7GR28W0FJIDACARBAZINEConfirmed FDA, NLM, Wikidata
- RxNorm 3098Confirmed FDA, Wikidata
- Wikidata Q416975dacarbazineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C411DacarbazineOne source FDA
- DrugBank DB00851One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D003606 | Dacarbazine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 7GR28W0FJI | DACARBAZINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 3098 | — | Confirmed FDA, Wikidata |
| Wikidata | Q416975 | dacarbazine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C411 | Dacarbazine | One source FDA |
| DrugBank | DB00851 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.